The CDMO will establish a Center of Excellence in North America, putting into operation a single-use bioreactor for the 93,000 square foot facility in Milford, MA, in the Greater Boston area.

The XDR-500 bioreactor, with a working volume of 100-500 L and downstream process capabilities of 2-8 g/L, is part of the state-of-the-art GMP facility suite concept. The system is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, e.g. multispecific antibodies.

Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Both, in Europe and the US, Rentschler Biopharma will be able to leverage its client-centric approach and expertise in advanced technologies to facilitate the robust and scalable production of complex biomolecules.